389 completed. 389 Phase 2, 40 Phase 1, 31 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 389 | Completed 389 |
| Phase 1 | 40 | Completed 40 |
| Phase 3 | 31 | Completed 31 |
Follow Hepatitis C: new trials by email Literature Review of Hepatitis C trials Research Report on Hepatitis C
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase 2, Safety and Efficacy of Bemnifosbuvir (BEM) and Ruzasvir (RZR) in Subjects With Chronic HCV Bemnifosbuvir, Ruzasvir - Chronic Hepatitis C Virus, Hepatitis C, Chronic | Phase 2 | Completed | Atea Pharmaceuticals, Inc. | 275 | 2023-05-30 | 2025-10-21 |
| Glecaprevir/Pibrentasvir for the Treatment of PTSD Glecaprevir / Pibrentasvir Pill - PTSD | Phase 2 / Phase 3 | Completed | White River Junction Veterans Affairs Medical Center | 10 | 2023-04-01 | 2024-08-29 |
| Radomised Phase II Study of MTL-CEBPA Plus Sorafenib or Sorafenib Alone MTL-CEBPA, Sorafenib - Hepatocellular Carcinoma, Hepatitis B | Phase 2 | Completed | Mina Alpha Limited | 8 | 2022-01-01 | 2025-03-06 |
| Prevention of Transmission of Hepatitis C Virus (HCV) From HCV-Viremic Organ Donor glecaprevir/pibrentasvir (GLE/PIB) - Hepatitis C, Hepatitis C Virus Infection, Response to Therapy of | Phase 1 / Phase 2 | Completed | University of California, San Diego | 12 | 2021-05-28 | 2022-05-24 |
| 8- Versus 12-week of Sofosbuvir-ravidasvir Treatment of Chronic Hepatitis C Sofosbuvir 400 MG, Ravidasvir 200mg - Hepatitis C | Phase 2 / Phase 3 | Completed | Muhammad Radzi Abu Hassan | 322 | 2021-03-23 | 2025-03-13 |
| The Tolerability, Pharmacokinetics and Pharmacodynamics Study of HEC110114 Tablets in HCV-infected Subjects HEC110114 Tablet, Sofosbuvir Tablet - Chronic Hepatitis C | Phase 1 / Phase 2 | Completed | Sunshine Lake Pharma Co., Ltd. | 24 | 2020-07-06 | 2020-09-10 |
| Glecaprevir/Pibrentasvir Fixed-dose Combination Treatment for Acute Hepatitis C Virus Infection Glecaprevir/Pibrentasvir (G/P) - Hepatitis C Infection, HIV Infection | Phase 2 | Completed | Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections | 45 | 2019-11-20 | 2024-07-11 |
| The Use of Hepatitis C Positive Livers in Hepatitis C Negative Liver Transplant Recipients sofosbuvir/velpatasvir - Liver Transplant, Hepatitis C | Phase 2 | Completed | Fernanda P Silveira, MD, MS | 5 | 2019-08-15 | 2026-04-30 |
| Study of AT-527 in Combination With Daclatasvir in Subjects With Hepatitis C Virus (HCV) Infection AT-527, Daclatasvir - Hepatitis C, Hepatitis C, Chronic | Phase 2 | Completed | Atea Pharmaceuticals, Inc. | 10 | 2019-06-20 | 2020-05-04 |
| Trial for the Treatment of Acute Hepatitis C for 8 Weeks With Sofosbuvir/Velpatasvir Sofosbuvir and Velpatasvir - Hepatitis C, Acute Hepatitis C | Phase 2 | Completed | Hannover Medical School | 20 | 2019-05-28 | 2021-07-06 |
| Utilization of Hepatitis C Positive Kidneys in Negative Recipients Sofosbuvir / Velpatasvir Oral Tablet [Epclusa], Glecaprevir/Pibrentasvir 100 MG-40 MG Oral Tablet [MAVYRET] - Kidney Transplant, Hepatitis C | Phase 2 / Phase 3 | Completed | Ohio State University | 54 | 2019-03-22 | 2023-09-13 |
| Pharmacokinetics of Ledipasvir/Sofosbuvir in Hepatitis C Virus-Infected Children With Hematological Malignancy Ledipasvir / Sofosbuvir Oral Product - Hepatitis C, Chronic, Hematologic Malignancy | Phase 1 / Phase 2 | Completed | Ain Shams University | 24 | 2019-03-01 | 2023-08-22 |
| Safety and Effectiveness of PRI-724 for Hepatitis C or B Virus Derived Liver Cirrhosis PRI-724 - Hepatitis C, Hepatitis B | Phase 1 / Phase 2 | Completed | Kiminori Kimura, MD | 27 | 2018-07-24 | 2024-10-10 |
| Study of CDI-31244 in Combination With Sofosbuvir (SOF) and Velpatasvir (VEL) CDI-31244, SOF/VEL - Chronic Hepatitis C | Phase 2 | Completed | Cocrystal Pharma, Inc. | 12 | 2018-06-26 | 2021-04-28 |
| A Study of the Use of Hepatitis C Positive Donors for Hepatitis C Negative Lung Transplant Recipients With Post-transplant Treatment With Mavyret Mavyret - Hepatitis C | Phase 2 | Completed | NYU Langone Health | 20 | 2018-05-12 | 2021-09-05 |
| To Evaluate Efficacy and Safety in TG-2349 Combination With DAG181 (± Ribavirin) in HCV Genotype I Infected Patients non-cirrhotic subjects. low TG-2349+ low DAG181+Ribavirin, non-cirrhotic subjects. high TG-2349+ high DAG181+Ribavirin, non-cirrhotic subjects. low TG-2349+ low DAG181 - Chronic Hepatics C Virus (HCV) Genotype 1, Non-Cirrhotic | Phase 2 | Completed | Dongguan HEC TaiGen Biopharmaceuticals Co., Ltd. | 133 | 2018-03-15 | 2021-02-18 |
| Treatment of Chronic Hepatitis C Infection by Ledipasvir/Sofosbuvir in Naïve Children Ledipasvir-Sofosbuvir 90 Mg-400 Mg Oral Tablet - Hepatitis C, Chronic | Phase 2 | Completed | Mansoura University Children Hospital | 50 | 2018-03-01 | 2021-10-25 |
| Role of Pegylated Interferon in Combination With DAAs to Cure Hepatitis C As Soon As Possible - Hepatitis C [ASAP-C] Sofosbuvir, Daclatasvir, Pegylated Interferon alfa-2a - Hepatitis C, Chronic | Phase 2 / Phase 3 | Completed | Johns Hopkins Bloomberg School of Public Health | 150 | 2018-02-02 | 2021-05-18 |
| Elbasvir (EBR)/Grazoprevir (GZR) in Pediatric Participants With Chronic Hepatitis C Infection (MK-5172-079) EBR/GZR FDC Tablet, Placebo, Grazoprevir Oral Granules - HCV Infection | Phase 2 | Completed | Merck Sharp & Dohme LLC | 57 | 2018-01-25 | 2023-05-31 |
| A Direct obserVed therApy vs fortNightly CollEction Study for HCV Treatment - ADVANCE HCV Study Elbasvir/Grazoprevir 50 MG-100 MG Oral Tablet, Psychological intervention, Sofosbuvir 400 MG - Hepatitis C | Phase 2 | Completed | University of Dundee | 129 | 2018-01-19 | 2021-11-18 |
Showing 20 of 389. Sign in to see all of them.
Hepatitis C, Chronic (194) · HIV Infections (24) · Hepatitis (21) · Fibrosis (15) · Liver Diseases (15) · Liver Cirrhosis (11) · Virus Diseases (8) · Hepatitis, Chronic (7) · Bronchiolitis Obliterans Syndrome (5) · Carcinoma, Hepatocellular (5) · Hepatitis B (5) · Coinfection (4) · Infections (4) · Acquired Immunodeficiency Syndrome (3)
Blood-Borne Infections (389) · Communicable Diseases (388) · Digestive System Diseases (387) · Flaviviridae Infections (387) · Hepatitis, Viral, Human (387) · RNA Virus Infections (386) · Infections (385) · Virus Diseases (381) · Liver Diseases (374) · Hepatitis (368) · Pathological Conditions, Signs and Symptoms (216) · Pathologic Processes (215) · Disease Attributes (199) · Chronic Disease (198) · Hepatitis, Chronic (191)
Ribavirin (198) · peginterferon alfa-2a (94) · Sofosbuvir (45) · daclatasvir (26) · peginterferon alfa-2b (26) · Ritonavir (22) · ledipasvir, sofosbuvir drug combination (22) · Simeprevir (19) · grazoprevir (17) · paritaprevir (17) · sofosbuvir-velpatasvir drug combination (17) · telaprevir (17) · ombitasvir (15) · elbasvir (12) · dasabuvir (11)
Gilead Sciences (50) · Merck Sharp & Dohme LLC (35) · Bristol-Myers Squibb (23) · Hoffmann-La Roche (16) · National Institute of Allergy and Infectious Diseases (NIAID) (15) · AbbVie (14) · Vertex Pharmaceuticals Incorporated (13) · AbbVie (prior sponsor, Abbott) (11) · ANRS, Emerging Infectious Diseases (10) · Boehringer Ingelheim (9) · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (8) · Romark Laboratories L.C. (6) · French National Agency for Research on AIDS and Viral Hepatitis (5) · Conatus Pharmaceuticals Inc. (4) · Debiopharm International SA (4)
United States (205) · France (67) · Puerto Rico (65) · Germany (62) · Canada (42) · Spain (38) · United Kingdom (35) · Australia (31) · New Zealand (29) · Belgium (27) · Italy (24) · Poland (21) · Austria (18) · Egypt (13) · Japan (12)
Asem Elfert, MD (4) · Daniel Cohen, MD (4) · Robert H. Hyland, DPhil (4)
PMID 28193518, PMID 30012435, PMID 30923816, PMID 30977945, PMID 24154738, PMID 24209977, PMID 24983020, PMID 25164700, PMID 25445400, PMID 25830171, PMID 26596948, PMID 26683763, PMID 26691547, PMID 26752189, PMID 28412293, PMID 28802814, PMID 28802816, PMID 31568620, PMID 15282352, PMID 15316341, PMID 15374882, PMID 15563253, PMID 15667486, PMID 15685543, PMID 15820563, PMID 15867490, PMID 16115185, PMID 16439867, PMID 16544259, PMID 16987047, PMID 17058240, PMID 17147494, PMID 17200799, PMID 17263626, PMID 17582705, PMID 17721093, PMID 17721100, PMID 18184077, PMID 18435468, PMID 18666223, PMID 18771667, PMID 19268724, PMID 19403902, PMID 19403903, PMID 19447518, PMID 19594300, PMID 19797971, PMID 19852040, PMID 19898214, PMID 20375406
2014 (12), 2009 (8), 2015 (8), 2016 (7), 2008 (4), 2004 (2), R01DA026727 (2), 2005 (1), 2017 (1), 2018 (1), 2019 (1), N01CN35160 (1), P50AT000009 (1), R01AI049141 (1), R01AI049508 (1)